BeStock  
Stocks › Biotechnology › KYMR

Kymera Therapeutics KYMR

US equityMarket cap rank #1426Biotechnology
$115.31 −$4.08 (-3.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $124.06 +7.59%
Open$117.89
Prev close$119.39
Day range$114.40 – $119.60
Volume1.28M
Market cap$9.84B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-35.0x
CheapRich

Near the bottom of its 5-year range · 3rd percentile, 5-year average -9.6x

Price / book6.7x
CheapRich

Near the top of its 5-year range · 97th percentile, 5-year average 4.0x

#4682 of 5336 stocks by PB (1 = cheapest)

Price / sales106.5x
CheapRich

Near the top of its 5-year range · 86th percentile, 5-year average 54.6x

#4965 of 5159 stocks by PS (1 = cheapest)

P/E over five years

-50x10x69x128xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$129.00
Price vs. fair value-10.6%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 6.75 – 3.98 97% (pricier than usual) #4682 of 5336 (1 = cheapest)
PE -35.05 -19.56 -9.55 3% (cheaper than usual) –
PS 106.53 415.22 54.59 86% (pricier than usual) #4965 of 5159 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on KYMR.

Sign in to join the discussion.

Scroll to Top